Which Racetam Fits Your Brain?
Last updated: October 3, 2026
This page profiles five compounds: aniracetam, oxiracetam, pramiracetam, phenylpiracetam, and omberacetam (often grouped with racetams). A single 1994 review (Gouliaev & Senning) drew on 407 references from 1965–1992 alone. There is no evidence-ranked 'best' racetam; most of the per-compound profiles below are community-reported.
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
The Science: What Racetams Do In Your Brain
The racetam family began with piracetam in the 1960s. Decades later, no generally accepted mechanism of action has emerged. The authors of one major 1994 review proposed that racetams potentiate neurotransmission that is already present rather than acting on receptors directly. This is their hypothesis, not an established finding (Gouliaev & Senning, 1994).
AMPA Receptor Hypothesis
No generally accepted mechanism of action has been established. The review authors' hypothesis is that racetams potentiate neurotransmission that is already present (possibly including enhanced sodium influx through AMPA-receptor-gated channels) rather than activating receptors directly. The review found no binding affinity for glutamate receptors.
Gouliaev & Senning, 1994, "Piracetam and other structurally related nootropics," Brain Research Reviews, PMID: 8061686
Neurotransmitter Turnover & Choline Pairing
Increased turnover of several neurotransmitters has been observed with racetams (Gouliaev & Senning, 1994). Users commonly pair them with choline and report headaches without it — a community practice, not something established in controlled studies.
Ion Channel Effects
The review authors' own hypothesis, not an accepted mechanism: racetams may potentiate calcium influx through non-L-type channels, enhance sodium influx through AMPA-gated channels, and may decrease potassium efflux.
Gouliaev & Senning, 1994
Safety Profile
"Racetams possess a very low toxicity and lack serious side effects." — Gouliaev & Senning, 1994. That review covered piracetam, oxiracetam, pramiracetam, etiracetam, nefiracetam, aniracetam and rolziracetam through 1992; it found no affinity for dopamine, serotonin, GABA (except nefiracetam), mu-opiate, or benzodiazepine receptors. Phenylpiracetam and omberacetam are not among the compounds it names.
Gouliaev & Senning, 1994 — review of 407 references, 1965–1992
The Social Butterfly
Users report smoother verbal expression and social ease (anecdotal).
What It Does
- Improved ADHD-like behaviors in a TARP γ-8 knockout mouse model (Sun et al., eNeuro 2025, PMID: 40118526) — an animal study, not tested in people with ADHD
Community-Reported Uses (Not Recommendations)
"Smoother verbal expression. Better ability to read social cues. Reduced social friction. You can still think analytically, but your emotions aren't flattened."
Community-Reported Profile
Analytical Speed
Users report faster processing on analytical tasks (anecdotal).
What It Does
- Piracetam-like nootropics, a group that includes oxiracetam, reversed scopolamine-induced amnesia in research models (Gouliaev & Senning, 1994)
Community-Reported Uses (Not Recommendations)
"Everything processes faster. Pattern recognition sharpens. Ideal for structured, analytical tasks requiring sustained clarity."
Community-Reported Profile
The Sniper
Users report narrow, tunnel-vision focus and some emotional flatness (anecdotal).
What It Does
- Partially reduced scopolamine-induced amnesia in healthy volunteers vs placebo (Mauri et al., 1994)
Community-Reported Uses (Not Recommendations)
"Tunnel vision. Everything non-essential fades. Cognitive resources directed entirely toward task completion. The emotional dampening is a feature, not a bug — if your task requires cold execution."
Community-Reported Profile
The Athlete
Users report cognitive and physical drive (anecdotal).
What It Does
- Adds a phenyl group to the piracetam structure
- S-phenylpiracetam is a selective dopamine transporter (DAT) inhibitor (PMID: 28743458)
- Listed (as 4-phenylpiracetam / carphedon) among WADA-prohibited stimulants in a 2008 review (Docherty, 2008 — stated in the full text, not the abstract); check the current WADA Prohibited List
- Phenotropil, of which S-phenylpiracetam is an optical isomer, is described as a clinically used nootropic (PMID: 28743458)
- The S-isomer reduced body weight gain in obese rodents without increasing locomotor activity (PMID: 28743458)
Community-Reported Uses (Not Recommendations)
"Locked in. Motivation and drive spike alongside cognitive clarity. The closest thing to 'feeling like the main character' in a nootropic."
Community-Reported Profile
The Long-Term Thinker
Users report effects that build over weeks (anecdotal).
What It Does
- Often grouped with racetams in nootropic communities; it is not one of the compounds covered by the 1994 review
- No studies are cited on this page for omberacetam; the profile below is community-reported
Community-Reported Uses (Not Recommendations)
"Subtle. You won't feel a switch flip. Over weeks, you notice better recall, faster pattern recognition, and more adaptive thinking. The marathon runner of racetams."
Community-Reported Profile
Side-by-Side: Pick Your Tool
Often grouped together, very different tools. Profiles below are community-reported, not taken from the cited studies.
Quick Decision (Community Reports)
Racetams and Choline Pairing
Choline pairing is a community convention: users commonly report headaches, brain fog, and diminished effects without it, on the theory that racetams increase acetylcholine use. This has not been established in controlled studies.
CDP-Choline
Also known as citicoline. The choline source most often mentioned in community racetam stacks.
Alpha-GPC
Another choline source commonly used in community stacks.
Choline Bitartrate
The lower-cost option. Community users often favor the other two; no head-to-head comparison is cited here.
Safety Profile & Legal Status
"Racetams possess a very low toxicity and lack serious side effects."— Gouliaev & Senning, 1994 — review of 407 references (1965–1992), Brain Research Reviews
Receptor Profile
For the racetams covered in the 1994 review, no affinity was found for dopamine, serotonin, GABA (except nefiracetam), mu-opiate, or benzodiazepine receptors. This does not extend to phenylpiracetam: S-phenylpiracetam is described as a selective dopamine transporter (DAT) inhibitor.
US Legal Status
Not FDA-approved in the United States. Products sold online are not FDA-approved drugs, so purity and dose accuracy are not assured.
International Status
Legal status varies by country. Always verify your local regulations.
Athletic / WADA
Phenylpiracetam (4-phenylpiracetam, carphedon) was listed among stimulants prohibited by the World Anti-Doping Agency (WADA) per a 2008 review (Docherty, 2008). Athletes should check the current WADA Prohibited List before using any racetam.
Key Takeaways
What the Research Supports
- No accepted mechanism yet; one review's authors hypothesize potentiation of existing neurotransmission (e.g., AMPA-gated ion flux)
- Very low toxicity reported for the racetams reviewed through 1992 (Gouliaev & Senning)
What to Be Careful About
- The clinical benefit described in the 1994 review was in patients with mild to moderate dementia, not healthy adults
- Choline pairing is common community practice, not established in trials
- "Enhancement" effects in healthy people are less well-documented
- Users report phenylpiracetam tolerance builds fast (anecdotal, not studied)
- Not FDA-approved in the US, so purity and dose accuracy are not assured
- Some users report pramiracetam feels emotionally flat (anecdotal)
- Don't stack multiple racetams without understanding each one first
- User reports vary widely between individuals
Sources & Citations
Gouliaev AH, Senning A. "Piracetam and other structurally related nootropics." Brain Res Brain Res Rev. 1994;19(2):180-222. Review of 407 references, 1965–1992.
Mauri M, et al. "Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers." Arch Gerontol Geriatr. 1994;18(2):133-9.
Zvejniece L, et al. "S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity." Pharmacol Biochem Behav. 2017.
Sun XL, et al. "Aniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice." eNeuro. 2025;12(3):ENEURO.0578-24.2025.
Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. 2008;154(3):606-22. (Full text lists 4-phenylpiracetam / carphedon among WADA-prohibited stimulants; the abstract does not name it.)
Explore More on HighPeptides
Nootropics Calculator
Dose, cycle, and stack planning
Modafinil Research Guide
The wakefulness agent, researched
All Peptide Guides
BPC-157, TB-500, and more
Peptide Calculator
Reconstitution and dosing math
Commonly Paired Supplements
Supplements users commonly pair with racetams (community practice, not trial-established)
Affiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Protocol & Stack Handbook ($19)
This page is for educational and informational purposes only. It is not medical advice. Racetams are not FDA-approved in the United States. Legal status varies by country. Consult a healthcare provider before using any nootropic compound. Cited studies are listed under Sources; onset, tolerance and effect profiles on this page are community-reported and anecdotal.
Related Resources
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.